Literature DB >> 21840276

Initiation of insulin among veterans with type 2 diabetes and sustained elevation of A1c.

Michael L Parchman1, Chen-Pin Wang.   

Abstract

AIM: To examine if the relationship between insulin initiation and glycemic control among veterans with poorly controlled type 2 diabetes (T2DM) varies by the number of oral-glucose-lowering-medication classes used prior to insulin initiation.
METHODS: The cohort consisted of veterans with T2DM with at least two glycosolated hemoglobins (A1c) ≥8.0% within a 12-month period but without prior insulin use. The study period was October 1998 until May 2006. Cox regression analyses were used to assess the predictors of the rate of insulin initiation.
RESULTS: Among 40,537 who met the inclusion criteria, 17,519 (43.2%) had insulin initiated over a median follow-up period of 58.6 months. The rate of insulin initiation due to 1% increase in A1c increased by 33.6%, 28.8%, 24.2%, 19.7%, 15.4% for patients exposed to 0, 1, 2, 3, 4 classes of oral-glucose-lowering agents. A higher insulin initiation rate was also associated with younger age, more comorbidities, non-Hispanic white race/ethnicity, obesity, longer diabetes duration, and attending endocrinology clinics.
CONCLUSIONS: Poor glycemic control is associated with increased rates of insulin initiation. This relationship is attenuated by the number of distinct oral-glucose-lowering-medication classes used prior to insulin initiation. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840276     DOI: 10.1016/j.pcd.2011.06.006

Source DB:  PubMed          Journal:  Prim Care Diabetes        ISSN: 1878-0210            Impact factor:   2.459


  8 in total

1.  Statins and Finasteride Use Differentially Modify the Impact of Metformin on Prostate Cancer Incidence in Men with Type 2 Diabetes.

Authors:  Wang Chen-Pin; Hernandez Javier; Carlos Lorenzo; John R Downs; Ian M Thompson; Bradley Pollock; Donna Lehman
Journal:  Ann Transl Med Epidemiol       Date:  2014

2.  Predictors of Insulin Initiation in Patients with Type 2 Diabetes: An Analysis of the Look AHEAD Randomized Trial.

Authors:  Scott J Pilla; Hsin-Chieh Yeh; Stephen P Juraschek; Jeanne M Clark; Nisa M Maruthur
Journal:  J Gen Intern Med       Date:  2018-01-19       Impact factor: 5.128

3.  Frailty Attenuates the Impact of Metformin on Reducing Mortality in Older Adults with Type 2 Diabetes.

Authors:  Chen-Pin Wang; Carlos Lorenzo; Sara E Espinoza
Journal:  J Endocrinol Diabetes Obes       Date:  2014

4.  Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients.

Authors:  Donna M Lehman; Carlos Lorenzo; Javier Hernandez; Chen-Pin Wang
Journal:  Diabetes Care       Date:  2012-03-28       Impact factor: 19.112

5.  Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy.

Authors:  S E Inzucchi; K Tunceli; Y Qiu; S Rajpathak; K G Brodovicz; S S Engel; P Mavros; L Radican; P Brudi; Z Li; C P S Fan; B Hanna; J Tang; L Blonde
Journal:  Diabetes Obes Metab       Date:  2015-06-22       Impact factor: 6.577

Review 6.  The impact of phenotype, ethnicity and genotype on progression of type 2 diabetes mellitus.

Authors:  Anand Thakarakkattil Narayanan Nair; Louise A Donnelly; Adem Y Dawed; Sushrima Gan; Ranjit M Anjana; Mohan Viswanathan; Colin N A Palmer; Ewan R Pearson
Journal:  Endocrinol Diabetes Metab       Date:  2020-01-07

7.  The longitudinal association between depressive symptoms and initiation of insulin therapy in people with type 2 diabetes in primary care.

Authors:  Giesje Nefs; Victor J M Pop; Johan Denollet; François Pouwer
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

8.  Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.

Authors:  Christina S Kwon; Enrique Seoane-Vazquez; Rosa Rodriguez-Monguio
Journal:  BMC Health Serv Res       Date:  2018-02-01       Impact factor: 2.655

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.